NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 358 filers reported holding NOVOCURE LTD in Q4 2020. The put-call ratio across all filers is 0.69 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $282,577 | -61.9% | 17,497 | -2.1% | 0.00% | -66.7% |
| Q2 2023 | $741,522 | -32.3% | 17,868 | -1.8% | 0.01% | -33.3% |
| Q1 2023 | $1,094,548 | -19.1% | 18,200 | -1.4% | 0.01% | -25.0% |
| Q4 2022 | $1,353,454 | -11.7% | 18,452 | -8.5% | 0.01% | -14.3% |
| Q3 2022 | $1,533,000 | +29.5% | 20,175 | +18.4% | 0.01% | +55.6% |
| Q2 2022 | $1,184,000 | -0.8% | 17,043 | +18.2% | 0.01% | +28.6% |
| Q1 2022 | $1,194,000 | -62.8% | 14,414 | -47.9% | 0.01% | -63.2% |
| Q3 2021 | $3,213,000 | -8.8% | 27,658 | +74.2% | 0.02% | -9.5% |
| Q2 2021 | $3,522,000 | +8.5% | 15,877 | -35.3% | 0.02% | 0.0% |
| Q1 2021 | $3,245,000 | -15.7% | 24,547 | +10.4% | 0.02% | -12.5% |
| Q4 2020 | $3,848,000 | +41.6% | 22,237 | -8.9% | 0.02% | +20.0% |
| Q3 2020 | $2,718,000 | -31.1% | 24,422 | -63.3% | 0.02% | -35.5% |
| Q2 2020 | $3,944,000 | +919.1% | 66,501 | +1348.2% | 0.03% | +933.3% |
| Q4 2019 | $387,000 | +66.1% | 4,592 | +3.1% | 0.00% | +50.0% |
| Q3 2018 | $233,000 | – | 4,454 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Invus Financial Advisors, LLC | 350,884 | $26,344,000 | 8.01% |
| HARTLINE INVESTMENT CORP/ | 318,109 | $23,884,000 | 3.27% |
| Deep Track Capital, LP | 550,000 | $41,294,000 | 2.92% |
| MORGAN JESS S & CO INC | 43,975 | $3,302,000 | 2.03% |
| Taylor Frigon Capital Management LLC | 46,376 | $3,482,000 | 1.09% |
| Darsana Capital Partners LP | 258,937 | $19,441,000 | 0.90% |
| Private Harbour Investment Management & Counsel, LLC | 13,562 | $1,018,000 | 0.81% |
| Rhenman & Partners Asset Management AB | 120,387 | $9,610,000 | 0.64% |
| COURAGE CAPITAL MANAGEMENT LLC | 10,000 | $751,000 | 0.50% |
| Baillie Gifford | 9,615,168 | $721,906,000 | 0.40% |